- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01642017
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria (VOTRAGE)
This is an open-label, multicenter, non-randomized, phase 1 dose escalation clinical trial to determine the MTD (Maximal Tolerated Dose) of Pazopanib in a population of frail elderly patients, selected according to the International Society of Geriatric Oncology (SIOG)classification (Group 2).
It is expected that a total number of 30 patients maximum will be enrolled in the study on 30 months : 18 months accrual - 12 months follow up.
Eligible patients will be enrolled into a standard 3+3 design with a starting dose of Pazopanib administered orally at 400 mg per day, in 28-day cycles. Then, further dose levels will be explored.
Toxicity of the schedule will be assessed during the first cycle. Patients will receive study medication until disease progression. After treatment discontinuation, patients will be followed during one year.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Bordeaux, France, 33075
- Hopital Saint André
-
Caen, France, 14076
- Centre Francois Baclesse
-
Lyon, France, 69008
- Centre Leon Berard
-
Toulouse, France, 31052
- Institut Claudius Regaud
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow up.
- Age ≥ to 75 years old
- Patient with metastatic cancer among renal cell carcinoma, non small cell lung cancer, pancreatic neuroendocrine cancer, sarcoma , ovarian cancer , thyroid cancer, bladder cancer or breast cancers, who cannot receive any treatment with curative intent.
- WHO PS ≤ 2,
- Life expectancy ≥ 3 months,
- Group 2 (vulnerable) according to SIOG classification,
- Adequate organ system function as defined in provided Table
Exclusion Criteria:
- Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA <1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed at low risk for recurrence by his/her treating physician,
- History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug.
- Criteria of group 3 according to SIOG classification,
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:
•Active peptic ulcer disease
•Known intraluminal metastatic lesion/s with risk of bleeding
•Inflammatory bowel disease (e.g. ulcerative colitis, crohn's disease), or other gastrointestinal conditions with increased risk of perforation
•History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:
•Malabsorption syndrome
•Major resection of the stomach or small bowel.
- Presence of uncontrolled infection.
- Corrected QT interval (QTc) > 480 msecs using Bazett's formula
- Anti-coagulants treatment (preventive or curative)
History of any one or more of the following cardiovascular conditions within the past 6 months:
• Cardiac angioplasty or stenting
• Myocardial infarction
• Unstable angina
• Coronary artery bypass graft surgery
- Symptomatic peripheral vascular disease
- Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
- Poorly controlled hypertension
- History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
- Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer
- Evidence of active bleeding or bleeding diathesis.
14 Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
15. Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug.
16. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
17. Unable or unwilling to discontinue use of prohibited medications list in Appendix 7 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study
18. Treatment with any of the following anti-cancer therapies:
- radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR
chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
19. Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity, except alopecia.
20. Patient not affiliated with social system in France.
21. Patient deprived of liberty or under guardianship
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Pazopanib
Pazopanib : 3 dose levels are defined : 400, 600 and 800 mg per day.
|
Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day).
The pazopanib will be administered at the same dosa until disease progression.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Dose limiting toxicity (DLT) incidence (according DLT definition) during the first treatment cycle with pazopanib (28 days)
Délai: 7.5 years
|
The MTD (Maximum Tolerated Dose) is defined as the highest dose level for which 6 patients were treated with a maximum of 1 patient presenting a DLT during the first cycle of treatment
|
7.5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Safety and tolerability assessments using the descriptions and grading scales found in the CTCAE (Common Terminology Criteria for Adverse Events) version 4.0 NCI
Délai: 7.5 years
|
7.5 years
|
|
Measure of Pazopanib plasma concentration during treatment period (objective : assessment of pharmacokinetics of Pazopanib in this population)
Délai: .8 time points (cycle 1 Day 1), 3 time points (cycle 1 D15) and 1 pre dose time point each day 1 of the following cycles (over a period of 7.5 years for measures in all patients)
|
Plasma concentrations of pazopanib will be determined using a validated LC-MS-MS method -
|
.8 time points (cycle 1 Day 1), 3 time points (cycle 1 D15) and 1 pre dose time point each day 1 of the following cycles (over a period of 7.5 years for measures in all patients)
|
Geriatric criteria measured by comprehensive geriatric assessment which evaluate medical, functional and psychosocial aspects of elderly patients
Délai: 7.5 years
|
The impact of treatment on the geriatric assessment will be done using :
|
7.5 years
|
Rate of objective response according to RECIST criteria
Délai: 7.5 years
|
Tumor assessment will be performed at screening visit, every 2 cycles and at the end of study visit and anytime if clinically indicated
|
7.5 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Loïc MOUREY, PhD, Institut Claudius Regaud
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 11GENE06
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Pazopanib
-
Cure HHTUniversity of North CarolinaPas encore de recrutementÉpistaxis | Télangiectasie hémorragique héréditaire
-
Illinois CancerCare, P.C.RésiliéCancer du poumon non à petites cellulesÉtats-Unis
-
Centre Leon BerardGlaxoSmithKlineComplétéCarcinome thyroïdienFrance
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Complété
-
Gynecologic Oncology GroupGlaxoSmithKlineRetiréLéiomyosarcome utérin
-
Novartis PharmaceuticalsComplétéCarcinome rénal métastatique | Carcinome à cellules rénales avancéEspagne, Allemagne, États-Unis, L'Autriche, Tchéquie, Royaume-Uni, Argentine, Hongrie, France, Canada, Chili
-
Samsung Medical CenterComplétéTumeurs solides réfractairesCorée, République de
-
Grupo Espanol de Investigacion en SarcomasGlaxoSmithKlineComplétéLiposarcome avancé et/ou métastatiqueEspagne, Allemagne
-
Grupo Espanol de Tumores NeuroendocrinosComplétéTumeurs neuroendocrines avancées/métastatiquesEspagne
-
Seoul National University HospitalSamsung Medical Center; Asan Medical Center; Seoul National University Bundang... et autres collaborateursRésiliéSarcome alvéolaire métastatique des parties mollesCorée, République de